Clinical trials: Healthy Adult Immune Response
HIV Infections
Safety and Immune Response to a Recombinant Adenovirus HIV-1 Vaccine in Healthy Adults
Successful control of the HIV epidemic will require a safe and effective vaccine to be developed. A successful vaccine will need to stimulate a widespread immune response.
- Trial name
- NCT00695877
- Testing
- Ad5.ENVA.48 HIV-1 vaccine
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza Prevention, Seasonal Influenza
Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS0116-00-VP (FluMos-v2) With and Without ALFQ Adjuvant in Healthy Adults
Background: Vaccines help the body learn to fight infections. Some vaccines are combined with adjuvants, which are added substances that make vaccines work better.
- Trial name
- NCT06863142
- Testing
- VRC-FLUMOS0116-00-VP, ALFQ
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Mild Gastrointestinal Symptoms in Healthy Adults, Low-grade Chronic Inflammation
Fungal Fiber for Gut Health
This study compares effects of plant based fiber vs fungi based fiber on clinical outcomes related to gut function (immunity, emotions, stress) and explores the role of gut microbiome structure and function on individual…
- Conditions
- Mild Gastrointestinal Symptoms in Healthy Adults, Low-grade Chronic Inflammation, Stress, Gut Health
- Trial name
- FUN4GUT (NCT06404749)
- Testing
- fungal fiber, inulin
- Where
- Argentina
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Future Biome SA
Dengue Fever
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3delta30/31-7164) in Healthy Adults
Dengue fever, which is caused by dengue viruses, is a major health problem in tropical and subtropical regions of the world. The purpose of this study is to test the safety of and immune response to a new dengue virus vaccine in…
- Trial name
- NCT00831012
- Testing
- rDEN3delta30/31-7164
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
AIDS
Evaluation of the Immune Response of a HIV Candidate Vaccine After Administration of One Chloroquine Dose
The purpose of this study is to evaluate the safety and reactogenicity of one booster dose of a HIV candidate vaccine after administration of one oral dose of chloroquine.
- Trial name
- NCT00972725
- Testing
- GSK Biologicals' HIV vaccine (732461), Chloroquine
- Where
- Belgium
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Conditions Influencing Health Status
Effects of Probiotics in Immune System of Healthy Adults
The present report describes the design of a clinical trial performed on healthy adult individuals to check whether the daily intake of the new Hero strains contribute to intestinal colonization, under safe and tolerable…
- Trial name
- SETOPROB (NCT01479543)
- Testing
- Probiotic CNCM I-4034, Probiotic CNCM I-4035, Probiotic CNCM I-4036
- Where
- 4 sites in Spain
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Hero Institute for Infant Nutrition
Dengue Virus
Safety and Immune Response to an Investigational Dengue Type 2 Vaccine
Dengue viruses can cause dengue fever and other serious health conditions, primarily affecting people living in tropical regions of the world.
- Trial name
- NCT01073306
- Testing
- Investigational Vaccine for Dengue Virus Subtype 2
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Aging, Older Adults
Supplement and Exercise Effects on Stationary Immunity and Health in Older Adults
The goal of this clinical trial is to learn whether a natural-origin nutritional supplement, combined with a moderate-intensity functional exercise program, can improve seasonal immunity, perceived health, and oxidative stress in…
- Trial name
- NCT07251244
- Testing
- Group 1: Exercise + nutritional supplement (EXNS)
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- University of Valencia
Safety of 25 ug of ChulaCov19-BNA159 mRNA Vaccine, Tolerability of 25 ug of ChulaCov19-BNA159 mRNA Vaccine
Safety and Immunogenicity of ChulaCov19 BNA159 mRNA Vaccine
This is a phase 1 study that will evaluate the safety and immunogenicity of ChulaCov19 BNA159 mRNA vaccine in healthy adults.
- Conditions
- Safety of 25 ug of ChulaCov19-BNA159 mRNA Vaccine, Tolerability of 25 ug of ChulaCov19-BNA159 mRNA Vaccine, Immune Response of 25 ug of ChulaCov19-BNA159 mRNA Vaccine, Safety of 50 ug of ChulaCov19-BNA159 mRNA Vaccine
- Trial name
- NCT05231369
- Testing
- ChulaCov19 BNA159 mRNA vaccine
- Where
- 2 sites in Thailand
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chulalongkorn University
Influenza A Virus, H5N1 Subtype
An Open-Label, Randomized Phase I Study in Healthy Adults of the Safety and Immunogenicity of Prime-Boost Intervals With Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc.) Administered Alone or Following Re...
Background: New vaccines against avian influenza, also known as "bird flu," are being developed and require testing to determine if they are safe and effective and whether they have any side effects.
- Trial name
- NCT01086657
- Testing
- VRC-AVIDNA036-00-VP, Monovalent Influenza Subunit Virion (Inactive H5N1) Vaccine
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Respiratory Syncytial Virus Infections
A First in Human Study to Evaluate the Safety and Immune Response to a Vaccine for the Treatment of a Respiratory Virus, When Administered Into the Arm in Healthy Adult Participants
Advanced Vaccine Laboratories Pty Ltd is developing a recombinant Respiratory Syncytial Virus (rRSV) vaccine for the protection of children (6 months to 5 years old) and the elderly from RSV infection.
- Trial name
- NCT04851977
- Testing
- Respiratory Syncytial Vaccine
- Where
- Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Advaccine (Suzhou) Biopharmaceuticals Co., Ltd.
Dengue Fever
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN1delta30) in Healthy Adults
Dengue fever, which is caused by dengue viruses, is a major health problem in tropical and subtropical regions of the world. The purpose of this study is to test the safety of and immune response to a new dengue virus vaccine in…
- Trial name
- NCT00089908
- Testing
- rDEN1delta30
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Herpes Zoster
Month 30 & 42 Extension Studies of CRD-004 Primary Study
The safety and immunogenicity of the GSK324332A vaccine has been evaluated up to Month 12 post-vaccination in the primary study.
- Trial name
- NCT00492648
- Testing
- Blood sampling for assay of persistence of immunogenicity
- Where
- Belgium
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis B
Development of Read-outs in Healthy, Hepatitis B Virus Naive Adults Vaccinated With the Hepatitis B Surface Antigen (HBsAg) in Combination With a GlaxoSmithKline (GSK) Biologicals' Adjuvant System
This study aims to develop innovative immunological read-outs and new technologies in order to further characterise the early immune response and its kinetics as well as the adaptive immune responses to adjuvanted vaccines.
- Trial name
- NCT01777295
- Testing
- Adjuvanted Hepatitis B surface antigen (HBsAg) candidate vaccine GSK2231392A., EngerixTM-B
- Where
- Belgium
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Tuberculosis
Biological Samples Obtained by Leukapheresis Induced by Two BCG Vaccinations in BCG-naïve Healthy Adults in the US
This protocol will use leukapheresis to collect lymphocytes to study immune responses following vaccination with BCG in BCG-naïve participants.
- Trial name
- (A-051) (NCT03175380)
- Testing
- bacillus Calmette-Guérin
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Aeras
Tuberculosis
BCG Revaccination Study in Diabetic and Non-Diabetic Adults
The purpose of this study is to: 1. explore whether investigators can make BCG more effective by giving it in a different way. For this, aerosol inhaled BCG will be compared against the conventional BCG injection. 2.
- Trial name
- NCT06246851
- Testing
- BCG Danish
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Marburg Virus Disease
Monovalent Chimpanzee Adenoviral-Vectored Marburg Virus Vaccine in Healthy Adults
A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral-Vectored Marburg Virus Vaccine in Healthy Adults
- Trial name
- NCT05817422
- Testing
- cAd3-Marburg vaccine
- Where
- 2 sites in Kenya, Uganda
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Albert B. Sabin Vaccine Institute
Dengue
Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine
Dengue viruses can cause dengue fever and other serious health conditions, primarily affecting people living in tropical regions of the world.
- Trial name
- NCT01506570
- Testing
- TetraVax-DV Vaccine - Admixture TV003, TetraVax-DV Vaccine - Admixture TV005
- Where
- 3 sites in United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza A Virus, H5N1 Subtype, Influenza A Virus
Phase I Open-Label Study of Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP, Encoding for Influenza Virus H5 Hemagglutinin Protein Given Intradermally
This study will evaluate the safety and effectiveness of a vaccine to prevent avian influenza (bird flu). About 25 to 50 million cases of influenza occur a year in the U.S., leading to 150,000 hospitalizations and 30,000 to…
- Conditions
- Influenza A Virus, H5N1 Subtype, Influenza A Virus, Influenzavirus A, Orthomyxovirdae
- Trial name
- NCT00489931
- Testing
- VRC-AVIDNA036-00-VP
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Rabies
Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis.
This is an exploratory trial to evaluate the effect of antimalarial drugs on the immune response generated by rabies vaccine when administered for post-exposure prophylaxis.
- Trial name
- MALRAB (NCT02564471)
- Testing
- Chloroquine, Atovaquone and Proguanil, Doxycycline
- Where
- United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- State University of New York - Upstate Medical University